Top Story

Roclatan demonstrates positive safety results at 12 months in phase 3 trial

July 20, 2017

Aerie Pharmaceuticals released successful 12-month safety results for the Mercury 1 phase 3 registration trial for Roclatan, a once-daily eye drop to lower IOP.

The 12-month safety and efficacy trial, which included a 90-day efficacy endpoint, showed consistent safety results for Roclatan, a combination of Rhopressa (netarsudil ophthalmic solution 0.02%) and latanoprost, with no new adverse events after the initial 90-day efficacy period of the trial, according to a company press release.

The Dry Eye

The state of dry eye care, part 2

Ocular Surgery News U.S. Edition, July 25, 2017
Darrell E. White, MD
As we head into the summer months, I thought it would be helpful to take the pulse of our dry eye world and report on the state of the state, if you will. In part 1 I…

Uveitis can complicate cataract surgery and limit vision gains

Ocular Surgery News U.S. Edition, July 25, 2017
Postoperative vision gains in eyes with uveitis that undergo cataract surgery are about a line less compared with healthy eyes that undergo the same procedure, according…

Sustained-release therapies remove patient factor from glaucoma treatment

Ocular Surgery News U.S. Edition, July 25, 2017
Sustained delivery devices that take glaucoma therapy out of patients’ hands may be the answer to the many issues related to adherence, with significant benefits…
Grand Rounds at the New England Eye Center

Man presents with blurry vision, flashes, floaters and redness

Ocular Surgery News U.S. Edition, July 25, 2017
Deborah Witkin, MD; Andre Witkin, MD
A 53-year-old Caucasian man presented with a 3-week history of worsening blurry vision of the left eye associated with flashes, floaters and redness. He also complained…
More News Headlines »
Clinical Science

Comparison of Ranibizumab and Bevacizumab for Macular Edema Secondary to Retinal Vein Occlusions in Routine Clinical Practice

Ophthalmic Surgery, Lasers and Imaging Retina, June 2017, Volume 48 Issue 6
To determine outcomes of intravitreal ranibizumab (IVR) (Lucentis; Genentech, South San Francisco, CA) versus…
More »

Non-infectious Uveitis: Moving Beyond the Standard of Care with an Eye on the Evidence

This activity is supported by educational grants from AbbVie, Inc.

Uveitis is one of the leading causes of preventable blindness worldwide with a prevalence in the US of about 38 cases…
More »
Resource Centers
Meeting News

VIDEO: Mitro updates Roclatan studies, Aerie financing

June 26, 2017
More »